Pilatus Raises $14M for First-in-Human Study of Anti-CD36 mAb

on

Pilatus announced raising $14 million to fund the first-in-human clinical study of its anti-CD36 monoclonal antibody (mAb).1

The news was reported as a top story by FirstWord Pharma, referencing Business Wire.1

Publication date:
December 15, 2025.1

Sources:

1. https://firstwordpharma.com/story/6745446